1 June 2018 - - Bethesda, Maryland-based immunotherapy products developer Northwest Biotherapeutics (NWBio) (OTCQB: NWBO) has published interim blinded survival data from its Phase 3 clinical trial of DCVax-L for newly diagnosed glioblastoma brain cancer in the peer reviewed Journal of Translational Medicine, the company said.
In this DCVax-L trial, 223 patients were ≥30 months past their surgery date as of this analysis; 30.0% have lived ≥30 months and these patients have Kaplan-Meier (KM) -derived median survival estimate of 46.5 months.
Also as of this analysis, 182 patients were ≥36 months past their surgery date; 24.2% have lived ≥36 months and these patients have KM-derived median survival estimate of 88.2 months.
The top 100 patients of the total 331 patients in the trial showed particularly extended survival, with median survival of 40.5 months from surgery. This extended survival was not fully explained by known prognostic factors.
Northwest Biotherapeutics is focused on developing personalized immunotherapy products designed to treat cancers both more effectively and more cost-effectively than current treatments, without toxicities of the kind associated with chemotherapies, in both North America and Europe. The company has a broad platform technology for DCVax dendritic cell-based vaccines.